Introduction
============

With the imaging technology advancement, and increasing awareness of early lung cancer screening, a growing number of cases presented with multiple primary lung cancer (MPLC) in clinical manifestation have taken place. Many studies have demonstrated significantly promising survival outcomes in patients with synchronous and metachronous MPLCs after surgical intervention.[@b1-ott-10-295]--[@b4-ott-10-295]

The most common histology of second MPLC is adenocarcinoma.[@b1-ott-10-295],[@b2-ott-10-295],[@b4-ott-10-295] Solitary lung adenocarcinoma has been widely investigated since the proposal by a joint working group of the International Association for the Study of Lung Cancer, American Thoracic Society, and European Respiratory Society (IASLC/ATS/ERS) in 2011.[@b5-ott-10-295] However, the prognosis of lung adenocarcinomas as the second MPLC has not been studied in detail. In addition, the characteristics and surgical treatment of the initial lung cancer can also potentially affect the prognosis of MPLC patients, which was not considered in previous studies.[@b1-ott-10-295],[@b3-ott-10-295],[@b4-ott-10-295]

In this study, the clinicopathologic features and prognosis of patients with a second primary lung adenocarcinoma (SPLAC) undergoing surgery were assessed.

Patients and methods
====================

Patients
--------

The study was approved by the ethics committee Patients of Shanghai Chest Hospital and the written informed consent was obtained from each participant in accordance with the institutional guidelines. All treatments were carried out in accordance with the approved guidelines and regulations. After looking through all the medical records of patients undergoing pulmonary resection for non-small cell lung cancer (NSCLC) during the period between January 2001 and December 2014, patients who underwent second resections for lung adenocarcinomas were retrospectively reviewed. A second primary lung cancer (SPLC) refers to a new primary lung cancer that develops after curative intent therapy for a first primary lung cancer. Both the initial and the second resections of NSCLC had been performed at the Department of Thoracic Surgery of Shanghai Chest Hospital, Shanghai, People's Republic of China.

Inclusion criteria mainly based on Martini--Melamed criteria:[@b6-ott-10-295] presence of tumors with different histologies (eg, adenocarcinoma versus squamous cell carcinoma), tumors of similar histology but arising from separate foci (eg, in the case of squamous cell carcinoma, the presence of in situ carcinoma in both tumors), a disease-free interval between the two lesions for at least 2 years, and tumors of similar histology in the absence of metastatic disease in intervening regional or mediastinal lymph node stations and the absence of extrathoracic disease. In addition, differing in histopathologic patterns of adenocarcinomas based on IASLC/ATS/ERS classification subtypes (eg, different estimated percentages of acinar versus bronchoalveolar versus papillary adenocarcinoma) were also considered as independent primary tumors.[@b5-ott-10-295]

A total of 182 patients were identified as second primary NSCLC. Of those, 115 patients had a second tumor with adenocarcinoma. All these patients had preoperative examination to exclude distant metastasis, which included chest computed tomography (CT) scan, abdominal CT or ultrasonography examination, brain magnetic resonance imaging, and whole body bone scan. Mediastinoscopy or endobronchial ultrasound-guided transbronchial needle aspiration or positron emission tomography was performed to exclude mediastinal lymphatic metastasis when the mediastinal lymph node enlargement (size \>1 cm).

Surgery
-------

Systematic and sampling lymph node dissection was performed in cases with lobar (lobectomy and extended lobectomy including sleeve lobectomy, lobectomy plus wedge resection, bilobectomy, and pneumonectomy) and sublobar (segmental and wedge resection), respectively.

Histologic and pathologic evaluation
------------------------------------

One senior pathologist reviewed all hematoxylin and eosin-stained slides and reevaluated histopathologic subtyping of lung adenocarcinoma according to the new classification.[@b5-ott-10-295] The tumor, node, and metastasis (TNM) stage was unified according to the seventh edition of the TNM classification for lung cancer.[@b7-ott-10-295]

Subgroups
---------

To increase the power of the analysis, three groups with low- (adenocarcinoma in situ, AIS; minimally invasive adenocarcinoma, MIA), intermediate- (lepidic-, acinar-, and papillary-predominant adenocarcinomas), and high-grade (solid-, micropapillary-, colloid-predominant, and invasive mucinous adenocarcinomas) adenocarcinomas were assigned for the patients with SPLAC according to the prognosis of IASLC/ATS/ERS classification subgroups reported by Yoshizawa et al.[@b8-ott-10-295]

The second adenocarcinomas, based on the CT morphology and consolidation/tumor ratio, were further divided into ground glass opacity predominant (GGO-p; including pure GGO and consolidation/tumor ratio ≤50% GGO) and solid predominant (Solid-p; including tumors with consolidation/tumor ratio \>50% and pure solid).

Statistical analysis
--------------------

Survival was calculated from the date of the second resection to the date of the last follow-up or death. Normally distributed continuous variables are presented as the mean ± standard deviation, otherwise as the median and range, while categorical variables are presented as numbers and percentages. Cumulative survival rates were calculated by the Kaplan--Meier method and compared using the log-rank test. Multivariate analysis was conducted using the Cox proportional hazards model after backward stepwise Wald elimination. All tests were two-sided and the level of significance was defined as *P*\<0.05. All statistical analysis was performed on SPSS version 19.0.

Results
=======

Patient characteristics
-----------------------

The clinical characteristics of patients are shown in [Table 1](#t1-ott-10-295){ref-type="table"}. The median interval between the primary tumor resection and resection of the second tumor was 28 months (range, 5--122 months). Before the first surgical intervention, the mean forced expiratory volume in 1 s (FEV~1~) was 2393.1±437.9 mL (99.7% of predicted value; range, 1,620--3,360 mL, 82%--113.3% of predicted value). Before the second surgical intervention, most of the patients (N=98; 85.2%) had an FEV~1~ \>60%.

The histopathologic distribution of the first and second resections was shown in [Table 2](#t2-ott-10-295){ref-type="table"}. With respect to the second resections, according to the prognostic of IASLC/ATS/ERS classification subtypes, three subgroups with low- (AIS, n=6; MIA, n=19), intermediate- (lepidic, n=9; acinar, n=40; papillary, n=23), and high-grades (solid, n=9; micropapillary, n=2; invasive mucinous, n=7) were assigned ([Table 3](#t3-ott-10-295){ref-type="table"}). Patients in the high-grade subgroup had the highest incidence of visceral pleura invasion (VPI; 44.4%), followed by the intermediate-grade subgroup (22.2%). There was no VPI in the low-grade subgroup. The high-grade subgroup was associated with more advanced pathologic stage.

Follow-up and survival
----------------------

The median follow-up time was 80 months (range, 17--191 months) after the first resection and 44 months (range, 12--125 months) after the second resection. By the time of the final follow-up, 33 patients had died. The 5-year overall survival (OS) rates from the time of the first and the second resections were 86.5% and 69.5%, respectively. In addition, of the five patients harboring epidermal growth factor receptor mutation managed with epidermal growth factor receptor tyrosine kinase inhibitors after the second resections, four patients were alive with good quality of life at 28, 40, 64, and 125 months, respectively, while one died, living for 96 months due to brain metastasis.

There was no significant difference in OS (*P*=0.888) between patients with an diagnosis interval ≤2 and \>2 years. The different types of the second resections demonstrated a slightly better 5-year OS (69.4% vs 63.6%; *P*=0.067) in patients who underwent lobar resections compared with sublobar resections, but statistical significance was not achieved. Univariate analysis was shown in [Table 4](#t4-ott-10-295){ref-type="table"}.

The different CT morphologies of the SPLAC demonstrated a significantly better OS in patients with GGO-p tumors compared with solid-p (adjusted hazard ratio \[HR\]=0.42; 95% confidence interval \[CI\], 0.19--0.94; *P*=0.036; [Figure 1](#f1-ott-10-295){ref-type="fig"}). The pathologic stage of the primary tumor had a significant influence on the survival (adjusted HR=0.25; 95% CI, 0.08--0.76; *P*=0.015; [Figure 2](#f2-ott-10-295){ref-type="fig"}). Furthermore, patients with similar/same histology had a better OS than the different counterparts (adjusted HR=0.06; 95% CI, 0.02--0.18; *P*\<0.001; [Figure 3](#f3-ott-10-295){ref-type="fig"}).

Patients in the low-grade subgroup were all alive (median follow-up, 42 months; range, 12--125 months) by the time of the final follow-up evaluation, except the patient who died 101 months after the second section. Intermediate-grade subgroup had a 5-year OS of 70.1%. High-grade subgroup had a 5-year OS of 42.2%. There were significant differences with respect to OS between patients in the low- and high-grade subgroups (adjusted HR=0.05; 95% CI, 0.01--0.58; *P*=0.016; [Figure 2](#f2-ott-10-295){ref-type="fig"}) and between the intermediate- and high-grade subgroup patients (adjusted HR=0.37; 95% CI, 0.15--0.89; *P*=0.027; [Figure 4](#f4-ott-10-295){ref-type="fig"}). Cox multivariate analysis was presented in [Table 5](#t5-ott-10-295){ref-type="table"}.

Discussion
==========

A number of patients with primary multiple malignancies are on the rise due to prolonged survival and advances in diagnostic techniques. In this study, we highlighted SPLACs because adenocarcinoma accounts for the majority of reported MPLC cases, and previous outcomes are heterogeneous due to a variety of metachronous second malignancies are included.[@b1-ott-10-295],[@b2-ott-10-295],[@b4-ott-10-295],[@b9-ott-10-295]--[@b11-ott-10-295]

Adenocarcinoma has high morphologic heterogeneity, and the new adenocarcinoma classification proposed by the IASLC/ATS/ERS provided precise preoperative[@b12-ott-10-295] or intraoperative diagnoses,[@b13-ott-10-295] and appropriate extent of resection for various early-stage adenocarcinomas.[@b13-ott-10-295],[@b14-ott-10-295] There is mounting evidence showing that different histomorphologic patterns in lung adenocarcinomas can be used to define prognostically variable subsets, and differentiating between low- and high-risk lung adenocarcinomas are of high clinical importance in the management of early-stage lung adenocarcinomas.[@b8-ott-10-295],[@b15-ott-10-295]--[@b17-ott-10-295] In the present study, three groups with low-, intermediate-, and high-grade adenocarcinomas were assigned for the patients with SPLACs according to the prognosis of IASLC/ATS/ERS classification subtypes.

As shown in previous studies,[@b8-ott-10-295],[@b17-ott-10-295] patients with solitary adenocarcinomas in the high-risk subgroup were associated with a high risk for recurrence or cancer-related death. The present study showed that patients with SPLACs in the high-grade group had the highest percentage of VPI, lymph node metastases, and relatively advanced pathologic stage, suggesting that this subgroup has a significant association with aggressive behavior that potentially favors early recurrence. Further analysis showed that there were significant differences in OS among patients in the low-, intermediate-, and high-grade subgroups when comparing the survival curves. Cox multivariate analysis identified histologic grade as a significant prognostic factor for OS, indicating that patients with SPLACs in the high-grade subgroup also have an increased risk for poor survival. The ongoing investigations facilitated by this new classification system were expected to provide guidelines for better management of patients with SPLACs.

Surgery offers the best chance for potential cure of SPLACs and provides most sufficient samples for diagnosis. In this study, we have shown a 5-year survival of 69.5% after resection of SPLACs, which was far better than expected for metastases or local recurrences.

Lobectomy remains the most effective treatment for patients with resectable primary NSCLCs. Although the survival outcomes of surgically treated MPLCs demonstrated in previous studies were very promising,[@b9-ott-10-295]--[@b11-ott-10-295],[@b18-ott-10-295] standard surgical strategies and the optimal extent of resection for the SPLCs have not been established owing to the lack of uniform criteria and prospective randomized trials. Generally, the extent of resection was based on the balance of risk and benefit of surgery, mainly considering characteristics of the tumor and performance status of patients, which might be different depending on individual surgeons. Regarding the extent of resection for the second tumors, the majority of the previous reports showed that sublobar resection is acceptable with comparable prognosis to anatomic lobar resections for SPLCs, appearing to support the use of limited resection in the treatment of metachronous lung cancer patients,[@b1-ott-10-295],[@b4-ott-10-295],[@b10-ott-10-295] which is inconsistent with some other studies.[@b9-ott-10-295],[@b19-ott-10-295] These outcomes are confusing because only the characteristics of the second tumor were analyzed and compared, even though the stage of the initial tumor might potentially affect the prognosis and not be completely reliable for drawing conclusions.

The surgical extent and pathologic stage of the first tumor are two potential factors that significantly influence the prognosis of SPLAC patients. We attempted to reduce possible bias by including some important characteristics of the initially resected tumors.

In this study, the different types of second resections demonstrated a slightly better 5-year OS in patients who underwent lobar resections compared with sublobar resections, but it did not reach statistical significance. Multivariate analysis did not identify sublobar resection of the primary or second tumor as a significantly negative prognostic factor. In our series, most (43/58, 74.1%) of the sublobar resections of the second adenocarcinomas were performed after the new classification, which might be responsible for this nonsignificant difference between lobar and sublobar resections in that the new classification could provide an effective approach to guide the resection strategy for primary adenocarcinoma.[@b13-ott-10-295] However, considering that most of the patients with second lesions in this study underwent anatomic lobar resections rather than limited resections before 2011, and many patients in the low-risk subgroup who underwent sublobar resections had the very short duration of follow-up, thus the long-term prognosis for limited resections of second adenocarcinomas based on the new classification is remained unclear. As a result, a longer duration of follow-up is needed. Also, other characteristics of the initially resected tumor, such as tumor CT morphology, and histologic classifications could be potentially confounding factors, thus further studies are warranted with homogenizing characteristics of the first resection as much as possible.[@b20-ott-10-295] Stereotactic body radiotherapy (SBRT) has emerged as the standard treatment for medically inoperable early-staged NSCLC.[@b21-ott-10-295],[@b22-ott-10-295] The local control rate after SBRT is \>90%. SBRT has also been widely adopted for the treatment of oligometastasis involving the lungs. Its possible applications in the treatment of SPLC are under extensive exploration.

Stage classification is essential because it allows consistent definition of patient groups, and thus provides a foundation for comparison of outcomes. For patients with MPLCs, however, the stage classification rules are ambiguous and confusing. Previous studies showed that pathologic stage of the second primary malignancies is demonstrated to be independent prognostic factor to predict survival without considering the potential influences caused by the stage of the first tumors.[@b1-ott-10-295],[@b23-ott-10-295] Our present study showed that both the pathologic stage of the first tumors and SPLACs significantly are prognostic factors, which further highlighted the complexity of MPLC staging. In this case, which one (initial versus second tumor) plays more important role in determining the prognosis of MPLCs or SPLACs requires further studies. Recently, proposals for the classification of lung cancers with multiple pulmonary sites of involvement in the forthcoming eighth edition of the TNM classification have been demonstrated,[@b24-ott-10-295] which might lead to greater consistency in classification of these multiple tumors while requiring further validations.

Limitations
===========

There were several important potential limitations in this study. The sample size was very limited. Due to the retrospective nature of the study, the results were based on a highly selected group of patients, thus there was certainly a degree of selection bias in the study. Even after adjusting some potentially affected factors of the primary tumors, other characteristics, and surgical treatment of the initial lung cancer could also affect patient survival, leading to potential bias as well. There were no molecular and genetic characteristics available for differentiating multiple lung cancers in our study. Despite of the wide popularity of Martini--Melamed criteria and the promising survival, there is possibility that some cases of solitary pulmonary metastasis might exist within our series could be included. Thus, the assessment of mutation testing in patients with multiprimary adenocarcinomas is strongly suggested.

Conclusion
==========

Surgical treatment can be considered for the management of SPLAC patients with promising survival outcomes. Tumor CT morphology of SPLACs and TNM status of the primary tumor and SPLACs were identified as predictors of long-term prognosis. The resection extent of primary tumor and SPLACs did not significantly affect 5-year survival of patients with SPLACs. The subgroups of SPLACs based on the new classification could provide additional prognostic information.
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###### 

Perioperative characteristics of the second intervention (N=115)

  Variables                                            First resection, n (%)   Second resection, n (%)
  ---------------------------------------------------- ------------------------ -------------------------
  Sex (%)                                                                       
   Male                                                                         55 (47.8)
   Female                                                                       60 (52.2)
  Age (years)                                                                   
   Median (range)                                                               60.0 (36--78)
  Smoking history                                                               
   Never                                                                        80 (69.6)
   Ever                                                                         35 (30.4)
  FEV~1~ (%)                                                                    
    ≤60                                                                         17 (14.8)
   \>60                                                                         98 (85.2)
  Tumor-free interval (years)                                                   
   \<2                                                                          63 (54.8)
    ≥2                                                                          52 (45.2)
  Surgical approach                                                             
   Thoracotomy                                                                  28 (24.3)
   Video-assisted thoracoscopic surgery                                         87 (75.7)
  Adjuvant chemotherapy after first/second resection                            
   Yes                                                 32 (27.8)                40 (34.8)
   No                                                  83 (72.2)                75 (65.2)
  ECOG PS before second resection                                               
   0--1                                                80 (69.6)                
   2                                                   35 (30.4)                
  Location                                                                      
   Ipsilateral                                         39 (33.9)                
   Contralateral                                       76 (66.1)                
  Computed tomography morphology                                                
   GGO-p                                               46 (40)                  73 (63.5)
   Solid-p                                             69 (60)                  42 (36.5)
  Type of resection                                                             
   Sublobar resection                                  21 (18.3)                58 (50.4)
    Wedge                                              18 (15.7)                37 (32.2)
    Segmentectomy                                      3 (2.6)                  21 (18.3)
   Lobar resection                                     94 (81.7)                57 (49.6)
    Lobectomy                                          88 (76.5)                56 (48.7)
    Extended lobectomy                                 3 (2.6)                  1 (0.9)

**Abbreviations:** ECOG, Eastern Cooperative Oncology Group; FEV~1~, forced expiratory volume in 1 s; GGO-p, ground glass opacity predominant; PS, performance status; Solid-p, solid predominant.

###### 

Histology of first and second resections

  Histology         First resection, n (%)   Second resection, n (%)
  ----------------- ------------------------ -------------------------
  Same/similar      93 (80.9)                
   AIS              1 (0.9)                  6 (5.2)
   MIA              8 (7.0)                  19 (16.5)
   Lepidic          7 (6.1)                  9 (7.8)
   Acinar           38 (33.0)                38 (33.0)
   Papillary        30 (26.1)                25 (21.7)
   Solid            6 (5.2)                  9 (7.8)
   Micropapillary   1 (0.9)                  2 (1.7)
   Mucinous         2 (1.7)                  7 (6.1)
  Different         22 (19.1)                
   SCC--AC          13 (11.3)                
   AS--AC           6 (5.2)                  
   LC--AC           3 (1.7)                  
  T stage                                    
   T1a              36 (31.3)                54 (47.0)
   T1b              25 (21.7)                13 (11.3)
   T2a              49 (42.6)                44 (38.3)
   T2b              2 (1.7)                  2 (1.7)
   T3               3 (2.6)                  2 (1.7)
  N stage                                    
   N0               91 (79.1)                87 (75.7)
   N1               27 (20.9)                16 (13.9)
   N2               0                        12 (10.4)
  TNM stage                                  
   Ia               57 (49.6)                71 (61.7)
   Ib               31 (27.0)                18 (15.7)
   IIa              22 (19.1)                11 (9.6)
   IIb              5 (4.3)                  2 (1.7)
   IIIa             0                        13 (11.3)

**Abbreviations:** AC, adenocarcinoma; AIS, adenocarcinoma in situ; AS, adenosquamous carcinoma; LC, large cell carcinoma; MIA, minimally invasive adenocarcinoma; SCC, squamous cell carcinoma; TNM, tumor, node, and metastasis.

###### 

Correlation of the predominant histologic subtype with pathologic stage and survival

  Group                Total   VPI   N0   N1   N2   Ia   Ib   IIa   IIb   IIIa   5-year OS
  -------------------- ------- ----- ---- ---- ---- ---- ---- ----- ----- ------ -----------------------------------------------
  Low grade            25      0     25   0    0    25   0    0     0     0      --[\*](#tfn3-ott-10-295){ref-type="table-fn"}
   AIS                 6       0     6    0    0    6    0    0     0     0      
   MIA                 19      0     19   0    0    19   0    0     0     0      
  Intermediate grade   72      16    54   11   7    42   14   6     2     8      70.1%
   Lepidic             9       3     4    3    2    3    1    3     0     2      
   Acinar              38      8     30   5    3    25   8    2     0     3      
   Papillary           25      5     20   3    2    14   5    1     2     3      
  High grade           18      8     8    5    5    4    4    5     0     5      33.0%
   Solid               9       5     4    2    3    1    3    2     0     3      
   Micropapillary      2       1     1    1    0    0    1    1     0     0      
   Mucinous            7       2     3    2    2    3    0    2     0     2      

**Notes:**

All data are censored. --, Not applicable, as more than half the number of patients were still alive.

**Abbreviations:** AIS, adenocarcinoma in situ; MIA, minimally invasive adenocarcinoma; VPI, visceral pleural invasion; OS, overall survival.

###### 

Univariate analysis of various potential prognostic factors for OS in patients with SPLAC

  -----------------------------------------------------------------------------------------------------------------------------------------------
  Variable                         Patients\   Median OS\                                     *P*-value
                                   (n)         (months)                                       
  -------------------------------- ----------- ---------------------------------------------- ---------------------------------------------------
  Gender                                                                                      0.628

   Male                            55          91.0±15.3                                      

   Female                          60          81.0±11.7                                      

  Age (years)                                                                                 0.679

    ≤60                            61          81.0±16.2                                      

   \>60                            54          96.0±31.2                                      

  Smoking history                                                                             0.824

   Never                           80          81.0±12.7                                      

   Ever                            35          91.0±13.5                                      

  Interval (months)                                                                           0.888

    ≤24                            63          96.0±33.7                                      

   \>24                            52          81.0±12.6                                      

  ECOG PS                                                                                     0.054

   0--1                            80          91.0±17.7                                      

   2                               35          66.0±11.0                                      

  Type of the first resection                                                                 0.072

   Sublobar resection              58          81.0±12.9                                      

   Lobar resection                 57          91.0±18.6                                      

  Type of the second resection                                                                0.206

   Sublobar resection              57          81.0±15.5                                      

   Lobar resection                 58          91.0±17.7                                      

  TNM stage of the primary tumor                                                              \<0.001[a](#tfn5-ott-10-295){ref-type="table-fn"}

   Stage I                                     101.0±5.8                                      

   Stage II                                    48.0±7.1                                       

  CT morphology of SPLAC                                                                      0.001[a](#tfn5-ott-10-295){ref-type="table-fn"}

   GGO-p                           73          --[b](#tfn6-ott-10-295){ref-type="table-fn"}   

   Solid-p                         42          59.0±8.0                                       

  Location                                                                                    0.308

   Ipsilateral                     39          67.0±27.5                                      

   Contralateral                   76          81.0                                           

  Histologic classification                                                                   0.001[a](#tfn5-ott-10-295){ref-type="table-fn"}

   Similar/same                    93          96.0±6.3                                       

   Different                       22          48.0±7.2                                       

  TNM stage of SPLAC                                                                          \<0.001[a](#tfn5-ott-10-295){ref-type="table-fn"}

   I                               83          --[b](#tfn6-ott-10-295){ref-type="table-fn"}   

   II                              19          66.0±11.2                                      

   IIIa                            13          32.0±7.6                                       

  Histologic grade of SPLAC                                                                   0.001[a](#tfn5-ott-10-295){ref-type="table-fn"}

   Low                             25          101.0                                          

   Intermediate                    72          91.0±15.7                                      

   High                            18          51.0±11.0                                      
  -----------------------------------------------------------------------------------------------------------------------------------------------

**Notes:**

Statistically significant.

Median survival unable to be estimated. Data presented as mean ± standard deviation. --, Not applicable, as more than half the number of patients were still alive.

**Abbreviations:** CT, computed tomography; ECOG, Eastern Cooperative Oncology Group; GGO-p, ground glass opacity predominant; MPLC, multiple primary lung cancer; OS, overall survival; PS, performance status; Solid-p, solid predominant; SPLAC, second primary lung adenocarcinoma; TNM, tumor, node, and metastasis.

###### 

Cox proportional hazards model of factors associated with survival in patients with SPLAC

  Characteristics                     Overall survival                
  ----------------------------------- ------------------ ------------ ---------
  CT morphology of SPLAC                                              
   GGO-p                              0.42               0.19--0.94   0.036
   Solid-p                                               Ref          
  Histology of MPLC                                                   
   Similar/same                       0.06               0.02--0.18   \<0.001
   Different                                             Ref          
  Pathologic stage of primary tumor                                   
   I                                  0.25               0.08--0.76   0.015
   II                                                    Ref          
  Pathologic stage of SPLAC                                           0.006
   I                                  0.21               0.08--0.56   0.002
   II                                 0.53               0.20--1.38   0.192
   IIIa                                                  Ref          
  Histologic grade                                                    0.019
   Low                                0.05               0.01--0.58   0.016
   Intermediate                       0.37               0.15--0.89   0.027
   High                                                  Ref          

**Abbreviations:** CI, confidence interval; CT, computed tomography; GGO-p, ground glass opacity predominant; HR, hazard ratio; MPLC, multiple primary lung cancer; Ref, reference; Solid-p, solid predominant; SPLAC, second primary lung adenocarcinoma.
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